Jiangsu Expressway Company Limited (JEXYF)

Market Cap	8.99B
Revenue (ttm)	3.38B
Net Income (ttm)	676.73M
Shares Out	n/a
EPS (ttm)	0.13
PE Ratio	13.28
Forward PE	11.62
Dividend	0.07 (5.26%)
Ex-Dividend Date	Jul 3, 2025

Volume	500
Average Volume	2,517
Open	1.300
Previous Close	n/a
Day's Range	1.300 - 1.300
52-Week Range	0.910 - 1.345
Beta	0.51
RSI	57.88
Earnings Date	Aug 28, 2025

About Theseus Pharmaceuticals

Jiangsu Expressway Company Limited, together with its subsidiaries, engages in investment, construction, operation, and management of toll roads and bridges in the People’s Republic of China. The company operates the Jiangsu section of Shanghai-Nanjing Expressway, Ningchang Expressway, Zhenli Expressway, Guangjing Expressway, Xicheng Expressway, Xiyi Expressway, Zhendan Expressway, Changyi Expressway, Yanjiang Expressway, Wuxi Huantaihu Expressway, Wufengshan Bridge, Longtan Bridge, Xitai Expressway, Danjin Expressway, Jiangyin Bridge, Sujiahan...

• Industry: Infrastructure Operations
• Sector: Industrials
• Founded: 1992
• Employees: 4,579
• Stock Exchange: OTCMKTS
• Ticker Symbol: JEXYF

Financial Performance

In 2024, JEXYF's revenue was 23.20 billion, an increase of 52.70% compared to the previous year's 15.19 billion. Earnings were 4.95 billion, an increase of 12.09%.